Googles Shweta Maniar writes about what shes learned traveling to conferences across the planet to talk about the convergence ...

Non-hallucinogenic neuroplastogens offer benefits over classical psychedelics, including simpler delivery, stronger IP ...

As new therapies for obesity enter the market, biopharmaceutical companies will need to tune commercial strategies to win ...

On this weeks Business of Biotech episode, Ebrahim Delpassand, M.D., founder, CEO, and chairman of the board at RadioMedix talks about his personal journey standing up and growing a ...

Catalyst Flex, a functional service provider (FSP) solution of Catalyst Clinical Research, is a multi-therapeutic niche contract research organization (CRO)with flexible, fit-for-purpose offerings in ...

Chris Anzalone, CEO of Arrowhead Pharmaceuticals, discusses overcoming adversity while leading the company through challenging times.

Pharma companies can benefit from conducting war games by gaining a better understanding of the external opportunities and challenges of all the key stakeholders in the industry.

Cybin CEO Doug Drysdale discusses learnings from psychedelic drug clinical trial missteps, provides examples of the benefits of FDA breakthrough therapy designation, and talks about why RFK Jr. as HHS ...

Part one of a two-part series that identifies current uses of AI in drug discovery and development and assesses whether AI tools improve the probability of success and likelihood of drug approval.

Managing risks associated with AI hallucinations requires "explainability," a process that identifies patterns or behaviors in AI models that are inconsistent with training data or logical ...

In the world of biopharmaceutical innovation, groundbreaking scientific discoveries often do not directly translate into commercial success. Simply developing a promising therapeutic based on great ...

When should a brand become two brands? Charles River Associates provide analyses and case studies of dual brands to elucidate the pros and cons.